Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Biosimilar Drugs Could Save Up to $110 Billion by 2020

Reuters Staff  |  March 30, 2016

LONDON (Reuters)—Lower-cost copies of complex biotech drugs, known as biosimilars, could save the U.S. and Europe’s five top markets as much as 98 billion euros ($110 billion) by 2020, a new analysis showed on Tuesday. Realizing those savings, however, depends on effective doctor education and healthcare providers adopting smart market access strategies, the report by…

Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use

Anne Harding  |  March 30, 2016

NEW YORK (Reuters Health)—Medical cannabis reduces chronic pain patients’ opioid use, while improving their quality of life, according to a new survey of Michigan cannabis dispensary patrons. “They report that when they make that switch they overall feel better,” Dr. Daniel J. Clauw of the University of Michigan, Ann Arbor, told Reuters Health in a…

Mediterranean Diet Tied to Lower Hip Fracture Risk

Andrew M. Seaman  |  March 29, 2016

(Reuters Health)—Women who maintain an overall healthy diet may benefit from a slightly reduced risk of hip fractures later in life, according to a new U.S. study. Women who followed a Mediterranean-style diet were about three tenths of a percent less likely to break a hip over about 16 years, compared to women who didn’t…

Mind-Body Therapy Helps Ease Chronic Low Back Pain

Andrew M. Seaman  |  March 26, 2016

(Reuters Health)—Mind-based therapy programs may help ease chronic back pain, new research suggests. Patients who took part in such programs were more likely to have noticeable and lasting improvements in back pain than those who stuck to their usual routines, investigators found. Both of the approaches tested in the study—mindfulness-based stress reduction (MBSR) and cognitive…

Combination Therapy Bests Monotherapy in Severe Postmenopausal Osteoporosis

Rita Buckley  |  March 25, 2016

NEW YORK (Reuters Health)—The combination of denosumab and teriparatide improves bone microarchitecture and estimated strength more than either drug alone in women with severe postmenopausal osteoporosis, researchers have found. Dr. Joy Tsai, from Massachusetts General Hospital in Boston, and colleagues conducted a single-site, two-year, open-label, randomized controlled trial involving 94 women aged 45 or older…

U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis

Reuters Staff  |  March 25, 2016

(Reuters)—U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co. to treat adults with moderate to severe cases of plaque psoriasis. The injectable drug known chemically as ixekizumab will be sold under the brand name Taltz, the U.S. Food and Drug Administration said. Taltz works by blocking interleukein-17A, a…

Health Insurer Anthem Sues Express Scripts over Drug Pricing

Reuters Staff  |  March 24, 2016

(Reuters)—Health insurer Anthem Inc. said it had sued pharmacy benefit manager Express Scripts Holding Co. to recover damages from drug pricing it believes was too high. The lawsuit, filed on Monday in U.S. District Court for the Southern District of New York, is the latest development in a month’s long dispute over Anthem’s contract with…

Older Americans Taking More Medications

Andrew M. Seaman  |  March 24, 2016

(Reuters Health)—The proportion of older Americans taking at least five medications or supplements went up in a recent study. The increase in people using multiple medications paralleled an increase in the number of older Americans at risk for major drug interactions, researchers found. “That’s a concern from a public health standpoint, because it’s getting worse,”…

FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers

Reuters Staff  |  March 23, 2016

(Reuters)—The U.S. Food and Drug Administration announced on Tuesday new required class-wide safety labeling changes for immediate-release opioid pain medications. Among the changes, the FDA now requires these pain medications to carry a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. The FDA also requires several additional safety labeling…

Knowledge of Genetic Risk Doesn’t Prompt Behavior Changes

Kathryn Doyle  |  March 23, 2016

(Reuters Health)—Telling patients about their genetic risk for disease doesn’t usually lead to healthy behavior changes, such as eating better or exercising more, according to a new analysis of existing studies. Researchers selected 18 studies that tracked seven potential behavior changes—such as quitting smoking, diet, physical activity and using sun protection—among people who had received…

  • « Previous Page
  • 1
  • …
  • 66
  • 67
  • 68
  • 69
  • 70
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences